They used quaternary combination immunotherapy: a TA targeting antibody to reduce tumor burden, an extended half-life recombinant half-life interleukin-2 for the expansion of effector lymphocytes, anti-PD-1 for boosting anti-tumor immune responses, and a potent T cell vaccine to trigger specific anti-tumor T cell responses.16 The gene discussed is IL2; the disease is neoplasm.